- Home
- GAMB vs BDTX Comparison
GAMB vs BDTX Comparison
Compare GAMB & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | BDTX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 116.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GAMB | BDTX |
|---|---|---|
| Price | $3.85 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $8.36 | ★ $9.67 |
| AVG Volume (30 Days) | 473.9K | ★ 827.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $8.79 | N/A |
| P/E Ratio | $89.96 | ★ $6.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.51 | $1.46 |
| 52 Week High | $13.83 | $4.94 |
Technical Indicators
Market Signals| Indicator | GAMB | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 49.14 |
| Support Level | $3.77 | $2.45 |
| Resistance Level | $4.55 | $2.79 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 81.71 | 15.93 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.